Meloksykam vs diklofenak w reumatologii Artykuł przeglądowy
##plugins.themes.bootstrap3.article.sidebar##
Opublikowane:
gru 31, 2023
Słowa kluczowe:
choroba zwyrodnieniowa stawów, niesteroidowe leki przeciwzapalne, NLPZ, reumatoidalne zapalenia stawów, spondyloartropatie, zesztywniające zapalenie stawów kręgosłupa
##plugins.themes.bootstrap3.article.main##
Abstrakt
Niesteroidowe leki przeciwzapalne stosowane w chorobach reumatycznych mają zmniejszać nasilenie bólu i reakcji zapalnej. Pacjent powinien je przyjmować przewlekle, dlatego wybrany preparat powinien charakteryzować się nie tylko skutecznością, ale także bezpieczeństwem. Obecnie w praktyce stosowane są preparaty nieselektywne i preferencyjne inhibitory COX-2. W pracy na przykładzie diklofenaku (lek nieselektywny) i meloksykamu (inhibitor COX-2) porównano skuteczność przeciwzapalną i przeciwbólową obu grup.
##plugins.themes.bootstrap3.article.details##
Jak cytować
Sikorska-Siudek, K. (2023). Meloksykam vs diklofenak w reumatologii . Medycyna Faktów , 16(4(61), 372-375. https://doi.org/10.24292/01.MF.0423.13
Numer
Dział
Artykuły
Copyright © by Medical Education. All rights reserved.
Bibliografia
1. Chen YF, Jobanputra P, Barton P et al. Cyclooxygenase-2 selective non-steroidal antiinflammatory drugs (etodolac, meloxicam, celecoxib, rofecoxib, etoricoxib, valdecoxib, lumiracoxib) for osteoarthritis and rheumatoid arthritis: a systematic review and economic evaluation. Health Technol Assess. 2008; 12: 1-278.
2. Dequeker J, Hawkey C, Kahan A et al. Improvement in gastrointestinal tolerability of the selective cyclooxygenase (COX)-2 inhibitor, meloxicam, compared with piroxicam: results of the Safety and Efficacy Large-scale Evaluation of COX-inhibiting Therapies (SELECT) trial in osteoarthritis. Br J Rheumatol. 1998; 37: 946-51.
3. Kang DO, An H, Park G et al. Cardiovascular and Bleeding Risks Associated With Nonsteroidal Anti-Inflammatory Drugs After Myocardial Infarction. J Am Coll Cardiol. 2020; 76: 518-29.
4. Yocum D, Fleschmann R, Dalgin P et al. Safety and efficacy of meloxicam in the treatment of osteoarthritis: a 12-week, double-blind, multiple-dose, placebo-controlled trial. The Meloxicam Osteoarthritis Investigators. Arch Intern Med. 2000; 160(19): 2947-54.
5. Efstathiou M, Settas L. The effect of non-steroidal anti-inflammatory drugs on matrix metalloproteinases levels in patients with osteoarthritis. Mediter J Rheumatol. 2017; 28(3): 133-41.
6. Ding Ch. Do NSAIDs affect the progression of osteoarthritis? Inflammation. 2002; 26(3): 139-42.
7. Rui-long X, Xia-hao L, Xian-tong K. Methotrexate in conjunction with meloxicam for treating ankylosing spondylitis: a clinical observation of the efficacy and safety. Di Yi Jun Yi Da Xue Xue Bao. 2003; 23(5): 460-2.
8. Auvinet B, Ziller R, Appelboom T et al. Comparison of the onset and intensity of action of intramuscular meloxicam and oral meloxicam in patients in acute sciatica. Clin Ther. 1995; 17(6): 1078-90.
9. Combe B, Vélicitat P, Garzón N et al. Comparison of intramuscular and oral meloxicam in rheumatoid arthritis patients. Inflamm Res. 2001; 50: 10-6.
10. Huskisson EC, Gholzan R, Kurthen R et al. A long-term study to evaluate the safety and efficacy of meloxicam therapy in patients with rheumatoid arthritis Br J Rheumatol. 1996; (35 suppl 1): 29-34.
11. Furst DE, Kolba KS, Fleischmann R et al. For The Meloxicam Rheumatoid Arthritis Investigators. Dose Response and Safety Study of Meloxicam Up to 22.5 mg Daily in Rheumatoid Arthritis: A 12 Week Multicenter, Double Blind, Dose Response Study versus Placebo and Diclofenac. J Rheumatol. 2002; 29: 436-46.
12. Sonsupap C, Pokhakul P, Kariya T et al. Characteristics of adverse drug reactions due to nonsteroidal anti-inflammatory drugs: a cross-sectional study. Nagoya J Med Sci. 2023; 85: 668-81.
13. Prieto A, De Barrio M, Martín E et al. Tolerability to nabumetone and meloxicam in patients with nonsteroidal anti-inflammatory drug intolerance J Allergy Clin Immunol. 2007; 119(4): 960-4.
14. Bavbek S, Dursun AB, Dursun E et al. Safety of meloxicam in aspirin-hypersensitive patients with asthma and/or nasal polyps. A challenge-proven study Int Arch Allergy Immunol. 2007; 142(1): 64-9.
15. CHARAKTERYSTYKA PRODUKTU LECZNICZEGO. Opokan-forte.
16. Euller-Ziegler L, Vélicitat P, Bluhmki E et al. Meloxicam: a review of its pharmacokinetics, efficacy and tolerability following intramuscular administration. Inflamm Res. 2001; 50: 5-9.
2. Dequeker J, Hawkey C, Kahan A et al. Improvement in gastrointestinal tolerability of the selective cyclooxygenase (COX)-2 inhibitor, meloxicam, compared with piroxicam: results of the Safety and Efficacy Large-scale Evaluation of COX-inhibiting Therapies (SELECT) trial in osteoarthritis. Br J Rheumatol. 1998; 37: 946-51.
3. Kang DO, An H, Park G et al. Cardiovascular and Bleeding Risks Associated With Nonsteroidal Anti-Inflammatory Drugs After Myocardial Infarction. J Am Coll Cardiol. 2020; 76: 518-29.
4. Yocum D, Fleschmann R, Dalgin P et al. Safety and efficacy of meloxicam in the treatment of osteoarthritis: a 12-week, double-blind, multiple-dose, placebo-controlled trial. The Meloxicam Osteoarthritis Investigators. Arch Intern Med. 2000; 160(19): 2947-54.
5. Efstathiou M, Settas L. The effect of non-steroidal anti-inflammatory drugs on matrix metalloproteinases levels in patients with osteoarthritis. Mediter J Rheumatol. 2017; 28(3): 133-41.
6. Ding Ch. Do NSAIDs affect the progression of osteoarthritis? Inflammation. 2002; 26(3): 139-42.
7. Rui-long X, Xia-hao L, Xian-tong K. Methotrexate in conjunction with meloxicam for treating ankylosing spondylitis: a clinical observation of the efficacy and safety. Di Yi Jun Yi Da Xue Xue Bao. 2003; 23(5): 460-2.
8. Auvinet B, Ziller R, Appelboom T et al. Comparison of the onset and intensity of action of intramuscular meloxicam and oral meloxicam in patients in acute sciatica. Clin Ther. 1995; 17(6): 1078-90.
9. Combe B, Vélicitat P, Garzón N et al. Comparison of intramuscular and oral meloxicam in rheumatoid arthritis patients. Inflamm Res. 2001; 50: 10-6.
10. Huskisson EC, Gholzan R, Kurthen R et al. A long-term study to evaluate the safety and efficacy of meloxicam therapy in patients with rheumatoid arthritis Br J Rheumatol. 1996; (35 suppl 1): 29-34.
11. Furst DE, Kolba KS, Fleischmann R et al. For The Meloxicam Rheumatoid Arthritis Investigators. Dose Response and Safety Study of Meloxicam Up to 22.5 mg Daily in Rheumatoid Arthritis: A 12 Week Multicenter, Double Blind, Dose Response Study versus Placebo and Diclofenac. J Rheumatol. 2002; 29: 436-46.
12. Sonsupap C, Pokhakul P, Kariya T et al. Characteristics of adverse drug reactions due to nonsteroidal anti-inflammatory drugs: a cross-sectional study. Nagoya J Med Sci. 2023; 85: 668-81.
13. Prieto A, De Barrio M, Martín E et al. Tolerability to nabumetone and meloxicam in patients with nonsteroidal anti-inflammatory drug intolerance J Allergy Clin Immunol. 2007; 119(4): 960-4.
14. Bavbek S, Dursun AB, Dursun E et al. Safety of meloxicam in aspirin-hypersensitive patients with asthma and/or nasal polyps. A challenge-proven study Int Arch Allergy Immunol. 2007; 142(1): 64-9.
15. CHARAKTERYSTYKA PRODUKTU LECZNICZEGO. Opokan-forte.
16. Euller-Ziegler L, Vélicitat P, Bluhmki E et al. Meloxicam: a review of its pharmacokinetics, efficacy and tolerability following intramuscular administration. Inflamm Res. 2001; 50: 5-9.